1. Scrip
  2. >>Focus On Asia

ASLAN, Sosei Pipeline Assets Hit By Development Delays

 
• By Ian Haydock

Two Asia-based companies disclose delays to important clinical pipeline assets, one in oncology driven by apparent ethnic differences in response to prior therapy and the other a CNS molecule hit by an unexpected toxicity finding in an animal study.

Scientist
SETBACKS FOR ASLAN, SOSEI CLINICAL PROJECTS • Source: Shutterstock

Two companies based in Asia have unveiled unexpected delays to the progress of key clinical-stage pipeline assets, and although analysts do not appear to be too concerned at this stage about the longer-term implications, the companies say there will be some impact and further updates are awaited as the events are analysed further.

Singapore-based Aslan Pharmaceuticals Pte. Ltd. said it expects to take around four months to review and implement a voluntary amendment to the protocol for an ongoing single-arm clinical trial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.